onvansertib + decitabine

**Onvansertib + decitabine** is a combination therapy consisting of onvansertib, an oral and highly selective polo-like kinase 1 (PLK1) inhibitor, and decitabine, a hypomethylating agent. Onvansertib targets PLK1, a serine/threonine kinase crucial for cell cycle regulation and is overexpressed in several cancers, notably acute myeloid leukemia (AML). Decitabine acts as a DNA methyltransferase inhibitor, leading to epigenetic reprogramming and cytotoxicity in malignant cells. The combination is under clinical investigation for relapsed/refractory AML and other hematologic cancers, showing synergistic anti-leukemic activity, especially in cases with spliceosome mutations, with good tolerability in early-phase studies. The therapy is administered as oral onvansertib plus intravenous decitabine in cycle-based regimens[1][3][5][2].